A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Cougar Biotechnology

Status and phase: Terminated; Phase 1

Conditions: Refractory Multiple Myeloma

Treatments: Drug: Noscapine HCl

Study type: Interventional

Funder types: Industry

Identifiers

NCT00912899

COU-NOS-001

Details and patient eligibility

About

This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety & tolerability of noscapine HCl in patients with advanced multiple myeloma

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced Multiple Myeloma.
• Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).
• ECOG performance status of either 0 or 1.

Exclusion criteria

• Prior chemotherapy with antimicrotubule agents
• Metastasis involving the brain or spinal cord
• Clinically significant lung or heart disease
• Abnormal electrocardiogram

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

One

Experimental group

Description:

Noscapine HCl

Treatment:

Drug: Noscapine HCl